News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
It is the first autotaxin inhibitor to be investigated in cancer patients
ANVISA issues CGMP to Concord Biotech’s Unit I
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Subscribe To Our Newsletter & Stay Updated
